| Literature DB >> 36034197 |
Shunping Huang1, Yang Xiao1, Heng Li1, Daochang Li1.
Abstract
With the changes of people's diet and lifestyle, the number of patients with abdominal malignant tumors is increasing year by year. In order to analyze the effectiveness of cone-beam CT (CBCT) enhancement technology in improving the accuracy of radiotherapy for clinical malignant tumors, 92 patients with abdominal malignant tumor are divided into the control group and the CBCT radiotherapy group. The experimental results show that precise radiotherapy technology can promote the recovery of the immune function of patients with abdominal malignant tumors, improve the effect of treatment, and decrease the incidence of complications.Entities:
Mesh:
Year: 2022 PMID: 36034197 PMCID: PMC9381236 DOI: 10.1155/2022/9696403
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
OBI safety and functional test items.
| The test items | A detailed description | Results |
|---|---|---|
| The door chain | If the shielding door of the accelerator room is not closed, we use the ray tube lock | Cannot send X-rays |
| Warning lights | All warning lights should be kept on during X-ray transmission | The warning light is on |
| Warning sound | When X-ray is transmitted, OBI manual control box should sound a warning sound | Warning tone appears |
| Collision detection and interlocking | In the process of KVS and KVD motion intentional collision, check whether the collision chain appears | Motion stops, warning lights, and warning sounds appear |
| OBI manual control box button | Release the manual box button during KVS and KVD motion | The movement stops |
| Injection line preheating | Step on the foot pedal to warm up the tube in perspective mode. The default preset parameters are 75 kV voltage, 50 mA current, and 32 ms exposure time | Executable operation |
| Functional | Examination data are transmitted from the treatment planning system to the treatment terminal, OBI workstation, and mechanical system | Executable operation |
OBI safety and functional test items.
| Content |
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| System error | 0.16 | 0.08 | −0.03 | 0.72 | 0.20 | 0.20 |
| The standard deviation | 0.20 | 0.41 | 0.22 | |||
| Random error | 0.06 | 0.14 | 0.11 | 0.25 | 0.25 | 0.18 |
| Placement outside enlarge | 0.54 | 1.07 | 0.66 |
Figure 1Isodose curve distribution of IMRT plan in patients.
Comparison of the total effective rate of clinical treatment (n, %).
| Group | CR | PR | SD | PD | Total clinical response rate |
|---|---|---|---|---|---|
| Conventional radiotherapy group ( | 12 (26.09) | 14 (30.43) | 15 (32.61) | 5 (10.87) | 26 (56.52) |
| CBCT group ( | 16 (34.78) | 22 (47.83) | 6 (13.04) | 2 (4.35) | 38 (82.61) |
|
| — | — | — | — | 7.393 |
|
| — | — | — | — | 0.007 |
Comparison of complications during treatment (n, %).
| Group | Radioactive damage | Digestive tract adverse reaction | Adverse reactions of the blood system | Total complication rate |
|---|---|---|---|---|
| Conventional radiotherapy group ( | 7 (15.22) | 6 (13.04) | 5 (10.87) | 18 (39.13) |
| CBCT group ( | 3 (6.52) | 3 (6.52) | 2 (4.35) | 8 (17.39) |
|
| — | — | — | 5.361 |
|
| — | — | — | 0.021 |
Comparison of immune function indexes (g/L, ‾x ± s).
| Group | IgG | IgA | ||
|---|---|---|---|---|
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Conventional radiotherapy group ( | 7.74 ± 0.43 | 7.65 ± 0.47 | 1.17 ± 0.22 | 1.18 ± 0.17 |
| CBCT group ( | 7.70 ± 0.35 | 12.36 ± 0.92∗ | 1.15 ± 0.18 | 4.25 ± 0.42∗ |
|
| 0.489 | −30.921 | 0.477 | −45.954 |
|
| 0.626 | <0.001 | 0.634 | <0.001 |
Comparison of survival time (month, ‾x ± s).
| Group | Progression-free survival time | Total survival time |
|---|---|---|
| Conventional radiotherapy group ( | 7.83 ± 1.64 | 14.85 ± 1.58 |
| CBCT group ( | 9.26 ± 1.37 | 20.28 ± 2.04 |
|
| −4.535 | −14.273 |
|
| <0.001 | <0.001 |